高水準的Mylan 不賣給低水準的Teva !!!

Mylan's stock falls after company rejects Teva's hostile buyout bid Published: Apr 27, 2015 9:42 a.m. ETMylan N.V.'s stock MYL, -5.71% slumped 3% in morning trade Monday, after the drug maker said its board of directors unanimously rejected Teva Pharmaceutical's TEVA, -4.32% unsolicited buyout bid. Mylan said it not only believes the bid Teva made early last week, which would value Mylan at about $40 billion, did not meet any of the key criteria that would cause the company to depart from its current course. "After thorough consideration, Mylan's Board unanimously determined that Teva's proposal grossly undervalues Mylan, and would require Mylan's shareholders to accept what we believe are low-quality Teva shares in exchange for their high-quality Mylan shares in a transaction that lacks industrial logic and carries significant global antitrust risk," said Mylan Chief Executive Robert Coury. Teva's stock shed 1.1% in early trade. On Friday, Mylan's stock had closed at a record high after the company raised its bid for Perrigo Co. PRGO, -2.39% to about $33 billion to help fend off Teva's hostile buyout attempt.

企业并购：Mylan称Teva出价太低；置疑Teva股票及成长前景Mylan执行董事长Robert Coury在致Teva的一份长长的带有批评语气的信件中说，对Mylan提出的每股82美元报价过低。Coury称，除非“报价起点大大超过每股100美元”，董事会才会考虑(合并)协商。这份信件于周一公布。华尔街分析师说过，Mylan可能希望把报价提高至每股90-95美元，并增加报价中的现金比重。Coury在信件中说，过去三年Teva的股价跑输包括Mylan在内的同业，是“不可接受的”。“Mylan董事会无意考虑这样一份意向书...要求Mylan股东接受以Teva股票为形式的低质高风险出价，”信件称。此外，信件还称，Mylan的客户和合作伙伴也不支持这起潜在的合并交易。(完)(编译 刘秀红/许娜/杜明霞；审校 王丽鑫/郑茵)